These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 22692505)

  • 1. Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival.
    Chang KH; Sanchez-Aguilera A; Shen S; Sengupta A; Madhu MN; Ficker AM; Dunn SK; Kuenzi AM; Arnett JL; Santho RA; Agirre X; Perentesis JP; Deininger MW; Zheng Y; Bustelo XR; Williams DA; Cancelas JA
    Blood; 2012 Jul; 120(4):800-11. PubMed ID: 22692505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear Vav3 is required for polycomb repression complex-1 activity in B-cell lymphoblastic leukemogenesis.
    Nayak RC; Chang KH; Singh AK; Kotliar M; Desai M; Wellendorf AM; Wunderlich M; Bartram J; Mizukawa B; Cuadrado M; Dexheimer P; Barski A; Bustelo XR; Nassar NN; Cancelas JA
    Nat Commun; 2022 Jun; 13(1):3056. PubMed ID: 35650206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway.
    Bassermann F; Jahn T; Miething C; Seipel P; Bai RY; Coutinho S; Tybulewicz VL; Peschel C; Duyster J
    J Biol Chem; 2002 Apr; 277(14):12437-45. PubMed ID: 11790798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene.
    Wang PY; Young F; Chen CY; Stevens BM; Neering SJ; Rossi RM; Bushnell T; Kuzin I; Heinrich D; Bottaro A; Jordan CT
    Blood; 2008 Nov; 112(10):4184-92. PubMed ID: 18755985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells.
    Waldron T; De Dominici M; Soliera AR; Audia A; Iacobucci I; Lonetti A; Martinelli G; Zhang Y; Martinez R; Hyslop T; Bender TP; Calabretta B
    Leukemia; 2012 Apr; 26(4):644-53. PubMed ID: 21960247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia.
    Hegde S; Gasilina A; Wunderlich M; Lin Y; Buchholzer M; Krumbach OHF; Akbarzadeh M; Ahmadian MR; Seibel W; Zheng Y; Perentesis JP; Mizukawa BE; Vinnedge LP; Cancelas JA; Nassar NN
    Leukemia; 2022 Mar; 36(3):637-647. PubMed ID: 34711926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bcr/Abl P190 interaction with Spa-1, a GTPase activating protein for the small GTPase Rap1.
    Yi SJ; Lee HT; Groffen J; Heisterkamp N
    Int J Mol Med; 2008 Oct; 22(4):453-8. PubMed ID: 18813851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced oncogenicity of p190 Bcr/Abl F-actin-binding domain mutants.
    Heisterkamp N; Voncken JW; Senadheera D; Gonzalez-Gomez I; Reichert A; Haataja L; Reinikainen A; Pattengale PK; Groffen J
    Blood; 2000 Sep; 96(6):2226-32. PubMed ID: 10979970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
    Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
    Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of Pax5 Exploits Sca1-BCR-ABL
    Martín-Lorenzo A; Auer F; Chan LN; García-Ramírez I; González-Herrero I; Rodríguez-Hernández G; Bartenhagen C; Dugas M; Gombert M; Ginzel S; Blanco O; Orfao A; Alonso-López D; Rivas JL; García-Cenador MB; García-Criado FJ; Müschen M; Sánchez-García I; Borkhardt A; Vicente-Dueñas C; Hauer J
    Cancer Res; 2018 May; 78(10):2669-2679. PubMed ID: 29490943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential motility of p190bcr-abl- and p210bcr-abl-expressing cells: respective roles of Vav and Bcr-Abl GEFs.
    Daubon T; Chasseriau J; El Ali A; Rivet J; Kitzis A; Constantin B; Bourmeyster N
    Oncogene; 2008 Apr; 27(19):2673-85. PubMed ID: 18059343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
    Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
    J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential interaction and activation of Rho family GTPases by p210bcr-abl and p190bcr-abl.
    Harnois T; Constantin B; Rioux A; Grenioux E; Kitzis A; Bourmeyster N
    Oncogene; 2003 Sep; 22(41):6445-54. PubMed ID: 14508524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukemogenesis of b2a2-type p210 BCR/ABL in a bone marrow transplantation mouse model using a lentiviral vector.
    Uchida N; Hanawa H; Dan K; Inokuchi K; Shimada T
    J Nippon Med Sch; 2009 Jun; 76(3):134-47. PubMed ID: 19602820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pak1 gene functioned differentially in different BCR-ABL subtypes in leukemiagenesis and treatment response through STAT5 pathway.
    Yuanxin Y; Yanhong Z; Qin Z; Sishi T; Yang D; Yi Z; Minjin W; Juan Z; Xiaojun L; Lanlan W; Binwu Y
    Leuk Res; 2019 Apr; 79():6-16. PubMed ID: 30784762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis.
    Gerboth S; Frittoli E; Palamidessi A; Baltanas FC; Salek M; Rappsilber J; Giuliani C; Troglio F; Rolland Y; Pruneri G; Kreutmair S; Pallavicini I; Zobel M; Cinquanta M; Minucci S; Gomez C; Santos E; Illert AL; Scita G
    Leukemia; 2018 Mar; 32(3):820-827. PubMed ID: 28819285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invadopodia and rolling-type motility are specific features of highly invasive p190(bcr-abl) leukemic cells.
    Daubon T; Rochelle T; Bourmeyster N; Génot E
    Eur J Cell Biol; 2012; 91(11-12):978-87. PubMed ID: 22717125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.
    Gu S; Chan WW; Mohi G; Rosenbaum J; Sayad A; Lu Z; Virtanen C; Li S; Neel BG; Van Etten RA
    Blood; 2016 Apr; 127(14):1803-13. PubMed ID: 26773044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo.
    Sengupta A; Arnett J; Dunn S; Williams DA; Cancelas JA
    Blood; 2010 Jul; 116(1):81-4. PubMed ID: 20407032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.
    Hemmeryckx B; Reichert A; Watanabe M; Kaartinen V; de Jong R; Pattengale PK; Groffen J; Heisterkamp N
    Oncogene; 2002 May; 21(20):3225-31. PubMed ID: 12082638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.